Other languages Omeros Corporation

Equities

OMER

US6821431029

Real-time Estimate Cboe BZX Other stock markets 09:15:03 29/04/2024 pm IST			5-day change	1st Jan Change
3.195 ^USD	+1.43%		+3.36%	-2.65%

01/04	Tranche Update on Omeros Corporation's Equity Buyback Plan announced on April 1, 2024.	CI
01/04	Omeros Corporation announces an Equity Buyback for $50 million worth of its shares.	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Omeros Corporation announces an Equity Buyback for $50 million worth of its shares.	02/04
Omeros Swings to Q4 Net Loss; Q1 Outlook Set	02/04
Omeros Corporation Provides Earnings Guidance for the First Quarter of 2024	02/04
Omeros Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	02/04
Omeros Corporation Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02/04
National Bank Raises DRI Healthcare Target to $22 on Omidria News, Guidance Increase	02/02
DRI Healthcare Trust Expands Royalty Entitlement on US Net Sales of Omidria, Updates Deployment and CAGR Guidance	01/02
Omeros Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	10/11
Omeros Corporation authorizes a Buyback Plan.	09/11
Omeros Corporation Announces Upcoming Presentations at ASH Annual Meeting	02/11
Novartis drug candidate scores interim win in rare kidney disease trial	30/23/30
Omeros Corporation Hires Andreas Grauer M.D. as Chief Medical Officer	19/23/19
US Equity Markets Close Higher Monday on Expectations for Upbeat Q3 Earnings	17/23/17
Sector Update: Health Care Stocks Rise Late Afternoon	17/23/17
Sector Update: Health Care	17/23/17
Top Midday Decliners	16/23/16
Omeros to Discontinue Phase 3 Trial of Narsoplimab After Failing to Reach Statistical Significance in Reducing Proteinuria	16/23/16
Omeros to shut kidney disease trial as therapy fails in late-stage study	16/23/16
Omeros Corporation Provides Update on Interim Analysis of ARTEMIS-IGAN Phase 3 Trial of Narsoplimab in IgA Nephropathy	16/23/16
Omeros Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	09/23/09

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Omeros Corporation

Equities

OMER

US6821431029

Other languages

Filters